Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase I/II, First-in-Human Study to Assess the Safety and Efficacy of Two Doses of SX600 Administered by Lumbosacral Transforaminal Epidural Injection in Patients With Radicular Pain Secondary to Lumbar Intervertebral Disc Herniation

Next Previous
Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase I/II, First-in-Human Study to Assess the Safety and Efficacy of Two Doses of SX600 Administered by Lumbosacral Transforaminal Epidural Injection in Patients With Radicular Pain Secondary to Lumbar Intervertebral Disc Herniation

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 12 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Back pain
  • Focus First in man; Proof of concept; Therapeutic Use
  • Acronyms SALIENT
  • Sponsors SpineThera

Most Recent Events

  • 19 Dec 2023 Status changed from completed to discontinued.
  • 25 Sep 2023 According to a SpineThera media release, data from this study has been accepted for presentation at the 22nd Annual Pain Medicine Meeting hosted by the American Society of Regional Anesthesia and Pain Medicine (ASRA).Dr. Lee Techner, will present the abstract at the conference.
  • 07 Dec 2022 According to a SpineThera media release, Dr. Bill Houghton is the medical director for this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top